long bone fracture, page-6

Ur right clave it simple Maths,
Pluristem can make a lot of cells for a lot less ,that's great so who's going to buy these cells ,I hear they are not as potent as msb's and their patents may be suspect.
Oh yes they have completed ONE phase 1trial !
At best in today's market they have a manufacturing advantage ,so they might make a $ out of that .

Athersys have great partner in Pfizer,unfortunately the partner is not coughing up and athersys had to raise $$ via private equity ,the market obviously loves them cause they sold the family silverware (4.3 mil shares and 4.3 million warrants ) for us$9million .....wow that's enough to fund a 20 mouse double blind trial !

And then you have the "dummies from msb" (. I am sure everybody is tired listening to this ,so every body apart from clave please stop reading now )
240 mil in the bank, pase 2's and phase 3's all over the place,a partner that's spending real doe building real products and milestone payments ...etc etc ,so yes champ it's simple Maths :)